Stocks to watch: Yanlord Land, Aims Apac Reit, Healthway Medical
Michelle Zhu
THE following companies saw new developments that may affect trading of their securities on Wednesday (Oct 11):
Yanlord Land Group : The Chinese property developer on Tuesday said it recorded 26.1 billion yuan (S$4.8 billion) in total contracted presales from residential units, commercial units and car parks for the first nine months of the year. This was a drop of 83.2 per cent compared to the corresponding period in 2022. Presales include those by the group, its joint ventures and associates. Prior to the news, shares of Yanlord Land ended S$0.015 or 2.4 per cent up at S$0.65.
Aims Apac Reit (AA Reit): Its manager on Tuesday reported a fire incident at one of the real estate investment trust’s properties at Yishun industrial park. The asset accounted for 0.9 per cent of total portfolio value and 1.2 per cent of gross revenue as at end-June 2023. Units of AA Reit closed S$0.02 or 1.6 per cent higher at S$1.30, before the news.
Healthway Medical : The closing date for the offer to acquire and delist the healthcare company at 4.8 Singapore cents per share has been extended to 5.30 pm on Oct 26. On Tuesday, shareholders of Healthway Medical were reminded that those who do not accept the offer will be “left holding shares in an unlisted company”. The counter ended S$0.001 or 2.1 per cent lower at S$0.047, before the announcement was made.
Trading halts: Australian residential property developer AVJennings and gold miner Wilton Resources called for trading halts ahead of market hours on Wednesday, pending the release of their respective announcements. Shares of AVJennings on the Singapore Exchange ended flat at AS$0.35 on Tuesday, and Wilton Resources closed unchanged at S$0.011.
TRENDING NOW
Once staunchly pro-China, Malaysian Chinese businesses are now distancing themselves from Beijing
AI can become superior to humans in certain aspects: TikTok’s Chew Shou Zi
DBS, OCBC, UOB face rate hike reality check
‘The market has spoken’: DBS CEO Tan Su Shan says market is repricing AI financing risks